Myocardial Infarction


Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education

No Image

By: Sara Riascos  May. 31, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Clopidogrel is a blood thinner used to prevent stroke, heart attack, and other heart problem. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  May. 30, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Clopidogrel is a blood thinner used to it can prevent stroke, heart attack, and other heart problems. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  May. 26, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing.Clopidogrel is a blood thinner used to prevent stroke, heart attack, and other heart problems. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  May. 23, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing.Clopidogrel is a blood thinner used to prevent stroke, heart attack, and other heart problem. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  May. 16, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing.Clopidogrel is a blood thinner used to prevent stroke, heart attack, and other heart problems. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  Apr. 12, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta(Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta(Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Read more

No Image

By: Sara Riascos  Apr. 11, 2022

Myocardial Infarctions are frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing.Clopidogrel is a blood thinner used to It can prevent stroke, heart attack, and other heart problem. Studies have shown that clopidogrel could reduce all-cause mortality and the probability of recurrent myocardial infarctions.

Read more

No Image

By: Sara Riascos  Mar. 25, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta (Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta (Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Read more

No Image

By: Sara Riascos  Mar. 24, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta (Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta (Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Read more

No Image

By: Sara Riascos  Mar. 15, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta (Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta (Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Read more